News - 2021

      December 31, 2021 Event

      Oblique’s Therapeutics AB (publ.) presentation at the virtual J.P. Morgan Healthcare Conference

      scheduled for Monday, January 10, 2022

      Read more

      December 6, 2021 News

      Award – Oblique Therapeutics AB (publ.) a Top Immunotherapy solution providers

      in Europe 2021

      Read more

      November 25, 2021 News

      Oblique Therapeutic’s AB (publ.) interim report for

      January – September 2021 (Q3 2021) is available.

      Read more

      November 18, 2021 Event

      Oblique Therapeutics AB (publ.) will be at the 3rd RAS/MAPK Pathway Targeted Drug Discovery Summit

      February 22- 24, 2022 Boston MA

      Read more

      November 16, 2021 News

      Oblique Therapeutics AB (publ.) welcomes Cecilia Larsson

      as IRM - Investor Relations Manager position at the Gothenburg Office

      Read more

      November 16, 2021 News

      Oblique Therapeutics AB (publ.) welcomes Mats Lindskog

      as CBO - Chief Business Officer working out from Stockholm Office

      Read more

      October 14, 2021 Event

      Oblique Therapeutics AB (publ.) presents its anti-Thioredoxin mAb program

      at the annual meeting of Society for Immunotherapy of Cancer, Nov 10 – 14, Washington DC, USA.

      Read more

      October 6, 2021 News

      New Press Article in Svenska Dagbladet

      in the INNOVATIVA FÖRETAG edition - October 2021

      Read more

      October 5, 2021 News

      Nobel Prize 2021 in Physiology or Medicine

      for discoveries of receptors for temperature and touch.

      Read more

      October 4, 2021 News

      Oblique Therapeutics AB (publ). announces that it has reached a key milestone

      in its aKRAS antibody program and achieved validation of its Abiprot® platform.

      Read more
      1 2 3 7